文献速递淋巴瘤

1990至2021年中国伯基特淋巴瘤疾病负担分析

[Analysis of the disease burden of Burkitt lymphoma in China from 1990 to 2021].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2026-01-01

基于2021年全球疾病负担研究数据,按年龄、性别和地区分层分析中国伯基特淋巴瘤(BL)的发病率、死亡率和伤残调整寿命年(DALY)。2021年中国BL新发1 322例,年龄标准化发病率为0.08/10万;1990至2021年年龄标准化发病率上升187.12%,而年龄标准化死亡率和DALY率分别下降37.72%和52.70%。疾病负担在年龄、性别和地区间存在显著差异。

要点

  • 2021年中国BL年龄标准化发病率为0.08/10万,死亡率为0.01/10万。
  • 80岁以上人群BL疾病负担最高,发病率达0.60/10万。
  • 1990至2021年BL年龄标准化发病率上升187.12%,死亡率下降37.72%。

核心结论

  • 中国BL疾病负担一定程度上有所减轻,但不同年龄、性别和地区间存在差异。
  • 应因地制宜针对不同人群制定综合防控策略以进一步降低BL疾病负担。

研究设计与样本

  • 基于2021年全球疾病负担研究数据,按年龄、性别、地区分层分析中国BL疾病负担。
  • 采用joinpoint软件回归分析计算年龄标准化率的平均年度变化百分比(AAPC),并与全球数据比较。

主要发现

  • 2021年中国BL新发病例1 322例,年龄标准化发病率0.08/10万;死亡241例,年龄标准化死亡率0.01/10万。
  • 2021年DALY为9 516人年,年龄标准化DALY率0.68/10万。
  • 80岁以上年龄组疾病负担最高,发病率0.60/10万、死亡率0.11/10万、DALY率1.59/10万。
  • 男性年龄标准化发病率0.11/10万高于女性0.05/10万,年龄标准化死亡率0.02/10万高于女性0.01/10万,年龄标准化DALY率0.92/10万高于女性0.43/10万。
  • 年龄标准化DALY率最高的地区为上海1.78(95% CI:0.16~3.63)/10万、西藏1.15(95% CI:0.41~2.23)/10万、青海1.06(95% CI:0.49~1.87)/10万。

关键数值与推荐

  • 2021年中国BL年龄标准化发病率0.08/10万,年龄标准化死亡率0.01/10万,年龄标准化DALY率0.68/10万。
  • 1990至2021年年龄标准化发病率增加187.12%,年龄标准化死亡率和年龄标准化DALY率分别降低37.72%和52.70%。
  • AAPC分别为3.49%、-1.46%和-2.40%。
  • 年龄标准化DALY率最低的地区为澳门0.32(95% CI:0.07~0.57)/10万、重庆0.36(95% CI:0.14~0.72)/10万、宁夏0.48(95% CI:0.25~0.92)/10万。

临床怎么用

  • 依据年龄、性别和地区差异识别BL高负担人群,因地制宜制定综合防控策略。
  • 关注80岁以上高龄人群及男性等疾病负担较高群体的诊疗需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: This study aimed to analyze the disease burden and trends of Burkitt lymphoma (BL) in China between 1990 and 2021. Methods: Based on the 2021 Global Burden of Disease Study data, stratified by age, sex, and region, the disease burden was analyzed by BL incidence, mortality, and disability-adjusted life year (DALY). Regression analysis was conducted with joinpoint software to calculate the average annual percentage change (AAPC) of age-standardized rates to analyze the changing trends and compare them with global data. Results: In 2021, a total of 1,322 new BL cases were reported in China, with an age-standardized incidence rate of 0.08/100,000. Of these patients, 241 died, with an age-standardized mortality rate of 0.01/100,000. DALY was 9,516 person-years, with an age-standardized DALY rate of 0.68/100,000. The disease burden of BL demonstrated significant differences across various age and sex groups. The highest BL disease burden was observed in the age group over 80 years old, with an incidence of 0.60/100,000, mortality of 0.11/100,000, and DALY rates of 1.59/100,000. BL disease burden was higher in males than in females, with age-standardized incidence rates of 0.11/100,000 and 0.05/100,000, age-standardized mortality rates of 0.02/100,000 and 0.01/100,000, and age-standardized DALY rates of 0.92/100,000 and 0.43/100,000, respectively. Significant regional differences were observed in BL disease burden. The highest-ranked age-standardized DALY rates were reported in Shanghai [1.78 (95% CI: 0.16-3.63) /100,000], Tibet Autonomous Region [1.15 (95% CI: 0.41-2.23) /100,000] and Qinghai Province[1.06 (95% CI: 0.49-1.87) /100,000], whereas the lowest-ranked were observed in Macao Special Administrative Region [0.32 (95% CI: 0.07-0.57) /100,000], Chongqing [0.36 (95% CI: 0.14-0.72) /100,000] and Ningxia Hui Autonomous Region [0.48 (95% CI: 0.25-0.92) /100,000]. From 1990 to 2021, the age-standardized incidence rate of BL increased by 187.12%, whereas the age-standardized mortality rate and age-standardized DALY rate decreased by 37.72% and 52.70%, respectively. The AAPCs were 3.49%, -1.46%, and -2.40%, respectively. Conclusions: The disease burden of BL in China has been alleviated to a certain extent; however, significant differences were observed among different ages, genders, and regions. Comprehensive prevention and control strategies should be formulated according to local conditions for different populations to further reduce the disease burden. 目的: 分析1990-2021年中国伯基特淋巴瘤(BL)的疾病负担和变化趋势。 方法: 基于2021年全球疾病负担研究数据,按照年龄、性别、地区分层,通过BL发病率、死亡率、伤残调整寿命年(DALY)分析疾病负担情况。采用joinpoint软件开展回归分析,计算年龄标准化率的平均年度变化百分比(AAPC)分析变化趋势,并与全球数据进行比较。 结果: 2021年,中国BL新发病例1 322例,年龄标准化发病率为0.08/10万;死亡病例241例,年龄标准化死亡率为0.01/10万;DALY为9 516人年,年龄标准化DALY率为0.68/10万。BL疾病负担在不同年龄和性别人群中存在差异,80岁以上年龄组的BL疾病负担最高,发病率、死亡率和DALY率分别为0.60/10万、0.11/10万和1.59/10万;男性BL疾病负担高于女性,男性和女性的年龄标准化发病率分别为0.11/10万和0.05/10万,年龄标准化死亡率分别为0.02/10万和0.01/10万,年龄标准化DALY率分别为0.92/10万和0.43/10万。BL疾病负担存在明显的地区差异,年龄标准化DALY率位于前列的省(自治区、直辖市)为上海市[1.78(95% CI:0.16~3.63)/10万]、西藏自治区[1.15(95% CI:0.41~2.23)/10万]、青海省[1.06(95% CI:0.49~1.87)/10万];位于后列的为澳门特别行政区[0.32(95% CI:0.07~0.57)/10万]、重庆市[0.36(95% CI:0.14~0.72)/10万]、宁夏回族自治区[0.48(95% CI:0.25~0.92)/10万]。1990-2021年,中国BL年龄标准化发病率增加了187.12%,年龄标准化死亡率和年龄标准化DALY率则分别降低了37.72%和52.70%,AAPC分别为3.49%、-1.46%、-2.40%。 结论: 中国BL疾病负担在一定程度上有所减轻,但在不同年龄、性别和地区之间均存在差异,应因地制宜地针对不同人群制定综合防控策略,以期进一步降低BL疾病负担。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zheng CH, Wang Y, Chen J, et al. [Analysis of the disease burden of Burkitt lymphoma in China from 1990 to 2021]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 41991310. doi:10.3760/cma.j.cn121090-20250813-00381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。